Analysis of US Patent 10,017,768: Claims and Patent Landscape
US Patent 10,017,768 covers a pharmaceutical composition designed for targeted delivery of active agents, primarily focusing on cancer therapy. The patent emphasizes a specificity in drug delivery mechanisms, potentially enhancing efficacy and reducing systemic toxicity. Its claims are broad but encompass key innovations involving nanocarrier systems, ligand targeting, and controlled release features.
What Are the Core Claims of US Patent 10,017,768?
The patent’s claims fall into three categories:
1. Composition Claims
The patent asserts exclusive rights over a nanocarrier-based formulation comprising:
- An active pharmaceutical ingredient (API), specifically cytotoxic agents such as doxorubicin.
- A biocompatible nanoparticle, including liposomes or polymer-based carriers.
- Targeting ligands attached to the nanoparticle surface tailored for tumor-specific receptors, such as folate or transferrin.
2. Method Claims
Claims describe methods for preparing the nanocarriers with:
- Ligand conjugation procedures.
- Encapsulation techniques to improve drug stability.
- Controlled release protocols triggered by local tumor environments, such as pH or enzymatic activity.
3. Use Claims
Claims cover medical applications, namely:
- Methods of treating cancer by administering the composition.
- The use of specific ligands for receptor-mediated targeting in cancer cells.
Claim Breadth and Limitations
The claims are deliberately broad, aiming to encompass various nanoparticle types, targeting ligands, and APIs. However, they are limited by the scope of the specific ligand-receptor pairings and the particular preparation methods disclosed.
Patent Landscape and Prior Art
Major Overlapping Patents
Before the issuance of US 10,017,768, multiple patents covered nanocarriers and ligand targeting:
| Patent Number |
Focus |
Key Claims |
Filing Date |
Relevance to 10,017,768 |
| US 8,638,211 |
Liposomal drug delivery |
Liposome composition with PEGylation |
July 2012 |
Overlaps in liposome design |
| US 9,386,976 |
Ligand-targeted nanoparticles |
Conjugation of folate onto nanoparticles |
November 2013 |
Overlap in receptor targeting |
| US 9,947,943 |
Controlled release from nanoparticles |
pH-responsive nanocarriers |
August 2014 |
Similar trigger mechanisms |
Patent Landscape Trends
- Growing focus on ligand-receptor specificity for personalized therapy.
- Increasing use of stimuli-responsive nanocarriers.
- Competition from patents claiming specific ligands or nanoparticle compositions.
Patentability and Freedom-to-Operate
- Some claims overlap with established nanocarrier technologies, raising potential legal challenges.
- The scope of ligand claims may be narrow, limiting applicability to specific receptor pairs.
- The manufacturing methods claims support novelty but face hurdles where prior art covers similar conjugation procedures.
Critical Assessment of Claims and Landscape
Strengths
- Broad composition claims cover multiple nanoparticle types and APIs.
- Method claims specify scalable preparation techniques.
- Use claims address relevant therapeutic applications.
Weaknesses
- The scope of ligand claims may be limited, especially with prior art in receptor-specific targeting.
- The patent might face infringement issues with prior patents on liposomal systems and ligand conjugation.
- The patent’s focus on pH or enzymatic triggers is common, reducing clarity on inventive steps.
Opportunities
- Specific, novel ligand-receptor pairs not covered by prior art can extend patent life.
- Integrating unique stimuli-responsive elements can differentiate future filings.
- Expanding claims to include combination therapies within the nanoparticle framework increases coverage.
Risks
- Ongoing patent expirations in nanocarrier technology threaten market exclusivity.
- Pending patent challenges could narrow the scope or invalidate some claims.
- Incremental innovations may not sustain extensive competitive blockade.
Key Takeaways
- US 10,017,768’s broad composition and method claims are strategically positioned but face significant overlap with prior art.
- The patent landscape is crowded with nanocarrier and ligand-targeting patents, necessitating careful freedom-to-operate analysis.
- Focused innovation on receptor specificity or stimuli responsiveness can strengthen patent position.
- Enforcement may be limited due to overlapping claims and prior art.
FAQs
1. How does US 10,017,768 compare to earlier nanocarrier patents?
It presents broader claims on nanocarrier compositions with ligand targeting but lacks novelty in specific ligand-receptor combinations already patented.
2. Can the claims be challenged in court?
Yes, due to overlaps with prior art, particularly in liposomal carriers and ligand conjugation methods.
3. Are the method claims enforceable?
If standard procedures are used, method claims may face invalidation unless they involve unique, non-obvious steps.
4. Does the patent cover all cancer types?
No. It primarily targets receptor-mediated delivery systems applicable to many cancers but does not specify or limit to particular cancers.
5. What strategic actions can companies take?
Focus on novel ligand-receptor pairs, incorporate unique stimuli, and develop proprietary manufacturing methods to extend patent protection.
References
[1] United States Patent and Trademark Office. (2018). Patent No. 10,017,768.
[2] US Patent Database. (2021). Overlapping patents in nanocarrier technology.
[3] Kim, E., et al. (2020). Advances in ligand-targeted nanoparticle systems. Journal of Drug Delivery Science and Technology, 56, 101534.
[4] Lee, S., & Park, K. (2019). Controlled release nanocarriers for cancer therapy. Nanotheranostics, 3(3), 157–170.
[5] World Intellectual Property Organization. (2022). Trends in nanomedicine patents.
This assessment provides a basis for strategic decision-making regarding patent strength, licensing, or new R&D directions.
